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Sexually Transmitted Infection (STI) screening, 
case and contact treatment, and condom promotion 
resulting in STI Reduction two years later in rural 
Malawi
   Abstract
As part of  a longitudinal cohort study in rural Malawi in 2000, 469 men 
and 758 women were asked to respond to a series of  surveys, were tested 
for gonorrhea and chlamydia, and received their results and treatment, 
if  applicable, for themselves and up to 2 partners if  positive for either 
sexually transmitted infection (STI).  Two years later, in 2002, 328 men 
and 525 women were again asked to respond to survey questions, tested 
again for gonorrhea and chlamydia, and were also tested for HIV – of  
these, 247 men and 453 women had also given urine samples in 2000.  In 
2000, the gonorrhea and chlamydia prevalence was 6.2% and 5.8% among 
men, and 3.6% and 4.9% among women. Two years later, prevalence of  
gonorrhea and chlamydia was 0.7% and 1.4% among men, and 1.3% and 
1.1% among women.  Although we did not test for HIV in the first round, 
the HIV prevalence in 2002 was 19.2%.  The implications of  the findings 
are discussed in the context of  interventions for STI prevention and to 
reduce HIV transmission in sub-Saharan Africa.
Introduction
Sexually transmitted infections (STIs) are a tremendous 
health and economic burden in developing countries1,2.  In 
Africa, excluding HIV, they are the second largest source 
of  healthy life years lost among women in fertile years 
(15-44 years old), resulting in a variety of  health problems 
including chronic pelvic inflammatory disease in women, 
urethral strictures in men, septicemia, and eye infections in 
newborns that can lead to blindness1,3.  They are estimated 
to account for 17% of  the economic losses due to ill health 
in developing countries1.  Moreover, the presence of  STIs 
increases the likelihood of  transmission and acquisition of  
human immunodeficiency virus (HIV)3-6.  For example, HIV 
shedding in semen was six times higher among men with 
gonococcal urethritis in Malawi than among men without 
this condition7.
Various strategies for decreasing STI prevalence in the 
general population have been proposed and implemented 
in different settings, including promotion of  safer sex, 
condoms, and early health care seeking behaviors; periodic 
presumptive treatment; partner notification and treatment; 
and syndromic management of  STIs, among others5.  There 
is no strong evidence about the effects of  partner notification 
strategies, though there is some indication that provider-led 
notification may work better than patient-led notification; 
however, some question this strategy, particularly in the 
context of  locations where sensitive and specific diagnostic 
tools are not available and where partner notification may 
be initiated without a positive diagnosis for an index case5,8.  
The effectiveness of  syndromic management and periodic 
mass treatment have both been rigorously evaluated as a way 
to decrease STI prevalence within communities, and though 
there are mixed results, it seems both methods can significantly 
reduce the prevalence of  curable infections9-12.  Specifically, 
syndromic management of  STIs has been promoted by the 
WHO for over a decade and subsequently incorporated by 
many STI control programs3.  Multiple studies have found 
this strategy effective in lowering the prevalence of  curable 
STIs in the general population and cost-effective as an 
intervention9-11,13,14.  However, syndromic management can 
only be effective if  the patient is experiencing symptoms. 
Various studies have suggested that syndromic management 
alone is not an effective STI control strategy, particularly 
due to the issue of  asymptomatic cases15,16.  For Chlamydia 
trachomatis (CT) alone, it is estimated that 70-75% of  women 
do not experience symptoms; this percentage is even higher 
for men3.  For Neisseria gonorrhoeae (GC), up to 80% of  
women may be asymptomatic, and approximately 10% of  
men, and these estimates vary widely3.  Additionally, some feel 
that syndromic management can lead to overdiagnosis and 
treatment of  STIs, resulting in increased costs to the system 
and potential drug resistance, amongst other problems2. 
Due to the costs and, in some countries, unavailability in 
obtaining laboratory testing for various STIs, improvements 
in rapid diagnostic testing of  STIs should have a profound 
effect on the implications of  syndromic management3.
Various studies have also examined whether STI treatment 
and control is an effective strategy to decrease HIV 
transmission and prevalence.  An initial study in Mwanza, 
Tanzania showed promising evidence that by using an STI 
prevention strategy that included syndromic treatment, 
one could expect to decrease HIV prevalence by as much 
as 40%9.  Three subsequent randomized controlled trials 
failed to show a significant effect of  STI control on HIV 
prevalence.  These latter studies include a mass STI treatment 
strategy in Rakai, Uganda, and two syndromic management 
interventions in Masaka, Uganda and eastern Zimbabwe10-12. 
Lower prevalence of  curable STIs due to less risky sexual 
behavior and the maturity of  HIV epidemic have been 
suggested as possible reasons for lack of  observed effect 
in these studies17.  Despite the lack of  observed association 
between intervention and HIV prevalence, mathematical 
models suggest that syndromic management of  curable STIs 
should remain cost-effective in highly HIV endemic areas, 
specifically where HIV prevalence is higher than 5%18. 
In Malawi, syndromic management was being implemented 
in all central/district hospitals and rural health centers in 
199319,20.  However, data from the 2004 Malawi Demographic 
and Health Survey, conducted soon after this study, revealed 
that only 27% of  women and 29% of  men with an STI or 
STI symptoms in the past 12 months reported seeking advice 
at a clinic or from a health professional; a larger percentage 
sought advice that was not from a health professional: 31% 
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of  women and 11% of  men reported they would seek advice 
from a traditional healer, 6% of  women and 8% of  men 
would seek advice or medicine from a pharmacy, and 21% 
of  women and 11% of  men would seek advice from friends 
or relatives21.
Data from the “Malawi Pregnancy and Sexually Transmitted 
Infection (STI) Risk Perception and Avoidance Study”, 
a prospective cohort study that took place in Mangochi, 
Malawi in 2000 and 2002, were used to examine the two 
main objectives of  this study: 1) to determine whether 
gonorrhea (GC) and chlamydia (CT) screening, combined 
with case and sexual partner treatment, as well as condom 
promotion, resulted in a reduction in the prevalence of  these 
STIs over 14-22 months; and 2) describe HIV prevalence in 
this sample22.  
Statement of the Problem
Setting
The study took place in the eastern lakeside region of  the 
Mangochi district, situated in southern Malawi near the 
border with Mozambique.  Mangochi is a predominantly 
rural district that in 2000 had an approximate population 
of  600,00023.  Most of  the people living in this district are 
from the Yao tribe, speak Chiyao and Chichewa, and are of  
Moslem faith23.  Within Malawi, one of  the poorest countries 
in the region, Mangochi is one of  the poorest districts, with 
some of  the lowest education and health indicators in the 
country24.  Mangochi is sub-divided into 11 traditional 
authorities, three of  which were selected for this study using 
probability proportional to size (PPS) methods22.  Within 
each of  these three TAs, four enumeration areas were 
selected22.
The estimated population in Malawi in 2000 was 11.8 
million25.  HIV prevalence was estimated to be 14.2% of  
adults at the end of  2003, with an estimated 84,000 deaths 
due to the disease in the same year26.  In 1995, 46% of  STI 
clinic patients tested at seven sites outside of  the major urban 
areas were HIV positive; more than half  of  those tested 
within the urban areas were diagnosed as HIV positive26.  
Study design
The Malawi Pregnancy and Sexually Transmitted Infection 
(STI) Risk Perception and Avoidance Study was a prospective 
cohort study that was conducted in two rounds.  A multistage 
cluster sample design was used to sample households wherein 
all eligible women and men were selected for interviews. 
At the first stage, three traditional authorities (TA) were 
selected from a total of  seven TA and two sub-TA using 
probability proportional to size (PPS).  At the second stage, 
four enumeration areas (EA) within each TA were selected 
again using PPS.  Households for each EA were enumerated. 
Households were then sampled from the list using a random 
starting point and a sampling interval that would provide the 
approximately 125 households per EA that we needed.  
The first round consisted of  weekly interviews for six 
consecutive weeks between June and December 2000. 
Field teams consisting of  groups of  four to five research 
assistants were based in housing arranged with the village 
chief.  The surveys included socio-demographic information; 
knowledge, attitudes and behaviors associated to a variety 
of  reproductive health topics (i.e., fertility, pregnancy, family 
planning, STIs, abortion, sexual behavior), based on our 
topics of  interest.  Due to the sensitive nature of  the topic 
and to build rapport, the same research assistant returned 
to interview his or her participants week after week.  In 
addition, in the third week, participants were also given the 
option to provide a urine sample for gonorrhea (GC) and 
chlamydia (CT) testing.  For those who consented to it, urine 
was collected in urine cups, and kept in coolers with frozen 
packs during the day.  The samples were moved daily to the 
District Hospital, where it was aliquoted, frozen at -20C, and 
transported to the University of  North Carolina at Chapel 
Hill (UNC-CH) in the United States for analysis using 
polymerase chain reaction (PCR)-based testing.  Because 
local capability for the PCR testing was not available at the 
Lilongwe Central Hospital (LCH) at that time, using funding 
from a National Institutes of  Health Fogarty International 
Center training grant, two technicians from the LCH lab 
were trained and conducted these analyses at UNC-CH. 
Results were available in the field within one month.  Those 
who tested positive for GC were given Ciprofloxacin 500mg 
or, among pregnant women, Erythromycin 500mg four 
times a day for seven days.  Men who tested positive for 
CT were given Doxycycline 100mg twice a day for seven 
days, and women who tested positive for CT were given 
Erythromycin 500mg four times a day for seven days.  The 
syndromic approach was too non-specific on which to base 
treatment options, primarily because of  the large number 
of  asymptomatic infections found among women.  These 
individuals were also encouraged to inform any sexual 
partners about this diagnosis and were provided treatment 
for up to two partners.  
The second round took place in March-May of  2002, 
between 14 and 22 months after the first round.  This 
round consisted of  weekly interviews for two consecutive 
weeks.  In the first week, participants were given the option 
of  providing urine samples for GC, CT and HIV testing. 
Urine collection, transport and testing was similar to that 
in the first round, except that the testing was now done in 
Malawi by the two trained LCH personnel.  Once again, 
those who tested positive were provided with treatment 
for themselves and up to 2 partners.  At the time of  the 
study, HIV rapid testing was not available or approved in 
Malawi, so venipuncture would have been required for HIV 
ELISA testing with blood. However, the Calypte HIV urine 
Western Blot (Calypte Biomedical Co., Portland, OR, USA) 
was available, so we were able to accurately detect HIV from 
urine samples in Malawi.  Pregnant women who were HIV 
positive were provided with a single dose of  nevirapine to be 
taken at labor and a dose of  nevirapine for their newborn at 
delivery.
While our field teams were in the communities in both 
rounds, they were adequately supplied with condoms that 
were handed out indiscriminately to anyone who asked about 
them or accepted our offer for them, and counseling on 
their use was provided to those interested.  Moreover, while 
in the field for the study, the team noted that at times the 
health posts ran out of  condoms, and they also made sure, in 
collaboration with the Mangochi District health office, that 
condoms were readily available at the health centers. 
STATA 11.0 was used for the data analysis27.  Frequencies 
for the various outcomes of  interest were calculated, and chi-
square and Fisher’s exact tests were used for comparisons.
Sample
Study respondents were drawn from a self-weighted 
probability sample of  1,390 households in the three traditional 
areas (TA) using probability proportional to size (PPS), as 
described above.  All occupants of  the sampled households 
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were enumerated, and all men between the ages of  20 and 44 
and all women between the ages of  15 and 34 were provided 
with information about this prospective cohort study, asked 
if  they were interested in participating, and if  so, the full 
IRB-approved consent process was carried out with each 
potential participant.  This yielded a total sample size of  915 
men and 1,192 women, of  which 737 men (80.7%) and 1,014 
women (85.1%) were successfully interviewed in the first 
week of  contact in round one.  Participation dropped every 
week (from reasons ranging from travel to unavailability to 
refusal); during week 3, when urine samples were collected, 
we had 635 men and 895 women participating (86.2 and 
88.3% of  those who participated in week 1).  The second 
round of  interviews and urine sample collections was 14-
22 months later: 451 men and 727 women participated at 
this time (61.2% and 71.7% participation rate, respectively, 
compared to the first week of  the first round of  the study). 
There were a total of  700 individuals, 247 men and 453 
women, who were screened in both rounds.  Most of  the 
analysis will focus on these 700 individuals for whom we 
have specimen data for both rounds.
Informed consent was obtained from each study participant 
and for each of  the various components of  this study: 1) 
agreement to participate in the survey portion, 2) agreement 
to be tested for GC and CT, and 3) agreement to be tested 
for HIV (only in round 2).  
This study was reviewed and approved by the Institutional 
Review Board (IRB) of  the University of  North Carolina 
at Chapel Hill, as well as the Malawian National Health 
Research Committee. 
Results
During the initial screening period of  July 2000 – January 
2001, 469/635 (73.9%) men and 758/895 (84.7%) women 
consented to GC and CT screening, and provided urine 
samples.  During the second round, March – May 2002, 
328/451 (72.7%) men and 525/727 (72.2%) women 
consented to STI screening, of  which 247 and 453 were 
tested during both rounds. All the analyses in this section are 
based on the 700 individuals who were screened in rounds 
one and two. A total of  573 individuals, 222 men and 351 
women, consented to HIV testing in round two.
The socio-demographic characteristics of  the study sample 
that were screened in rounds one and two, and both 
rounds, are presented in Table 1.  In all rounds, those with 
a higher education and a higher perceived risk for STI were 
more likely to give urine than those with 4 years or less of  
education and low/small perceived risk (not shown in table 
1).  There were no detectable differences among those who 
participated in rounds one versus two, particularly examining 
for differences in demographics, perception of  risk for STIs, 
or STI symptoms or history. 
Among those who were tested in both rounds (n=700), 
prevalence of  GC and CT in the first round was 4.7% 
and 5.7%, respectively, and 10% of  those whose urine was 
sampled were positive for at least one of  these (see Table 
2).  In the first round, GC prevalence was lower among 
women than men (3.3% and 7.3%, respectively, P = 0.018), 
and CT prevalence was also slightly lower among women 
than men, though the difference for CT was not significant 
(5.1% and 6.9%, respectively).  Prevalence for GC and/or 
CT combined was also slightly lower for women (8.4%) than 
men (13.0%) (P = 0.054).
Table 1: Socio-Demographic Background and Perceived Risk for STIs 
Among Individuals Screened for STIs in Rounds One and Two, and in 














20-24 32.4 28.1 28.3
25-29 28.0 28.8 30.7
30-34 17.4 18.9 18.4
35-39 (only men) 12.8 13.9 13.4
40-44 (only men) 9.8 11.5 10.9
Gender
Male 38.2 38.5 35.3
Female 61.8 61.5 64.7
Education
None 38.0 39.0 38.1
1-4 years 26.7 27.5 26.4




None 38.0 39.0 50.1
Small-Moderate 22.7 24.0 22.1
Great 20.8 23.2 25.9
Occupation
Farm-related 50.7 52.9 53.7
Skilled 8.5 8.2 8.7
Trade 18.5 18.1 16.9
Other 22.6 21.2 21.0
Mobility a






a Mobility defined as having been gone from home for over a month in 
the past year. Men were asked if they had been gone for over a month 
in the past year, whereas women were asked if their male partners had 
been gone for over a month in the past year.
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Table 2.  STI Prevalence and Incidence Among Participants Screened in 








a Indeterminate: 3.1 (18/573); men 2.3 (5/222); women 3.7 (13/351)
In the second round, the overall GC prevalence was 1.3% and 
the overall CT prevalence was 1.4%; an approximately five 
fold decrease in each, though this difference is not statistically 
significant.  The prevalence of  GC was slightly lower for men 
(0.8%) than women (1.6%), and the prevalence of  CT was 
almost identical among men (1.6%) and women (1.3%) – 
none of  these gender differences were significant.  Urine was 
not tested for HIV in round one, but the overall prevalence 
in our sample was 17.5% (only 573 individuals accepted 
being tested for HIV, hence the smaller denominator; there 
were an additional 3.1% that were indeterminate).  HIV 
prevalence was slightly higher for women (18.5%) than men 
(15.8%), though the difference was not significant. 
None of  those who were positive for GC and/or CT in the 
first round and who were re-screened in the second round 
were re-infected (not shown).  Of  the 37 people infected and 
treated for GC in round one, 33 were re-screened at round 
two and none were re-infected with GC.  Likewise, of  the 46 
who were infected and treated for CT in round one, 40 were 
re-screened and none were re-infected with CT. 
Within our sample of  individuals screened during rounds 
one and two, self  reported condom use increased following 
the first screening and treatment period from 12.6% to 
13.4% (P = 0.000).
The percentage of  men and women reporting any STI 
symptom at round one and two is presented in Table 3. 
For women, the symptoms included lower abdominal pain, 
foul smelling discharge, genital sores or ulcers, genital warts, 
burning pain on urination, redness or inflammation of  
genitals, or genital itching.  For men, the symptoms included 
urethral discharge, genital sores or ulcers, genital warts, 
burning on urination, and painful swelling in groin area. 
Table 3.  Reported STI Symptoms by Gender
There were no significant associations found between any 
of  the reported current symptoms (individual symptoms 
or reporting at least one symptom) and STI infection for 
either sex in the first round (not shown in table).  In the 
second round, among men there was a statistically significant 
association between GC infection and urethral discharge (P 
= 0.000), as well as pain at urination (P = 0.041).  Among 
women in the second round, abdominal pain (P = 0.015), 
genital warts (P = 0.003), and pain at urination (P =0.009) 
were significantly associated with having GC infection. 
None of  the symptoms were significantly associated to being 
infected with CT. 
Discussion
There are significant programmatic and policy implications 
from our findings.  First, one recognized successful 
intervention for STI prevention28 - and one of  the widely 
discussed strategies for HIV prevention29-30, albeit with mixed 
findings in the literature - is STI screening and treatment.  We 
found an approximately five fold decrease in the GC and CT 
prevalence in the 14-22 months following a representative 
population based screening that also involved treatment 
for cases and up to two contacts, condom promotion, and 
health education on use of  condoms.  Though this reduction 
was not statistically significant, none of  the individuals who 
were GC or CT positive in the first round and who received 
treatment were re-infected in the second round of  the study. 
In the context of  the literature on partner notification, 
the approach taken in this study – of  actually giving out 
treatment for the positive index case and up to two partners 
– is different than the strategy examined in various studies 
consisting of  notifying partners whether via patient him/
herself  or via a health provider and based on reported 
symptoms, but one that may be worth studying further.  Like 
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any strategy, it will have it pros and cons, one of  which is that 
it could result in other unintentional uses for the treatments 
if  not monitored (i.e., treatment for partners could be sold 
to others for profit). 
More research is also needed to determine if  STI screening 
and case/partner treatment is cost effective and relevant in 
sub-Saharan African settings to reduce the prevalence of  
asymptomatic STI for HIV prevention29-30.  The only way to 
determine if  the STI screening and treatment approach taken 
in this study has an effect on HIV acquisition/transmission 
in this setting is to continue to monitor HIV prevalence/
incidence while continuing the STI screening and treatment 
program.  In this study, there was only one round of  testing 
for HIV.
Findings from this study regarding the poor association 
between reported STI symptoms and actual STI infection 
in both periods are not surprising considering what is 
known about the large percentage of  asymptomatic cases 
of  STIs.  Namely, the most likely explanation for the lack 
of  association between reported STI symptoms and testing 
positive for gonorrhea and chlamydia is that there is simply 
a large percentage of  individuals who are asymptomatic. 
There are also other possible explanations.  Our survey was 
conducted face-to-face and it is possible people abstained 
from reporting any symptoms with our study team due to the 
sensitive nature of  the topic or for other reasons.  Various 
studies have revealed that social desirability bias influences 
what is discussed in face-to-face interviews, particularly as 
it relates to sexual practices (with the bias working in both 
directions)31.  To reduce social desirability bias, the research 
team ensured that the same research assistant interviewed 
the same participant throughout all rounds of  the study 
(there was only a small amount of  staff  turnover) and that 
questions of  a more sensitive nature were asked in later 
interviews (questions on STI symptoms were in week 2); 
interestingly, reported STI symptoms were higher in the 
second round than in the first, despite a lower prevalence of  
GC and CT infection.  The Malawi National Statistical Office 
uses the same technique used by this study team for self-
reporting of  STI symptoms; self  reported STI symptoms 
were similar to those observed in the second round of  this 
study: 4% of  men and 4.8% of  women reported a genital 
discharge, and 4.4% of  men and 8.0% of  women reported a 
genital sore or ulcer32. 
There was also a statistically significant increase in reported 
condom use between the two rounds.  Though it could be 
due to social desirability bias as well – the participants knew 
that this practice is valued in general – it might also be the 
result of  health education on condom use that was given out 
by the research team during the approximately two months 
that the teams lived in each of  the communities during round 
one, and the team’s distribution of  condoms to anyone who 
asked for them.
Conclusion
This longitudinal study in Malawi involved survey and 
biospecimen collection in 2000 and 2002, with treatment 
provided to STI cases identified in each round and up to two 
of  their partners.  We did not test the partners (unless they 
were also participants in our study) nor did we supervise the 
distribution of  antibiotics for the partners; it is possible that 
uninfected individuals were treated or that infected partners 
did not take their treatment dose.  We are not able to confirm 
if  all antibiotics for infected partners were used per our 
recommendation.  However, despite the lack of  statistical 
significance, the five fold decrease in GC and CT between 
rounds one and two, and lack of  re-infection among those 
treated for GC and CT in the first round, is promising and 
warrants further exploration.
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